Be Alert for Rare Risks with Janus Kinase Inhibitors (Xeljanz, Etc)

Risks with tofacitinib (Xeljanz, Xeljanz XR) are stacking up.

Xeljanz already has a boxed warning about serious infections...malignancy... thrombosis...and mortality.

Now FDA is alerting about more evidence that Xeljanz is associated with cancer (lung, etc)...and CV events (heart attack, etc).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote